TORONTO, Nov. 1, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce announced the voting results from its Annual General and Special Meeting of Shareholders held on Monday…


Previous articlePT369 – Chronic Pain and Phantom Limb Pain: Could Psilocybin Be the Answer?
Next articlePharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome